On March 23, 2022, the FDA approved the therapeutic radiopharmaceutical agent Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan, also known as 177Lu-PSMA-617) for treatment of metastatic prostate cancer detected on prostate-specific membrane antigen (PSMA) PET imaging. ^[1]U.S. Food & Drug Administration. FDA approves Pluvicto for metastatic castration-resistant prostate cancer Silver Spring (MD): U.S. Food & Drug Administration; 2022 [cited 2022 6 July]. … Continue reading ^[2]FDA approves Pluvicto/Locametz for metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63(5):13N-N. Agents targeting PSMA have become important in both the diagnostic and therapeutic approaches to prostate cancer.

A recent multicenter randomized open-label trial, evaluated the efficacy of Pluvicto™ in a subset of patients who had not responded to certain treatment regimens. Overall survival was improved with Pluvicto™ compared to standard treatment.

This represents an example of the expanding field of theragnostics, in which a particular structure specific to a disease state is targeted by paired diagnostic and therapeutic agents. ^[3]Marin JFG, Nunes RF, Coutinho AM, et al. Theranostics in nuclear medicine: emerging and re-emerging integrated imaging and therapies in the era of precision oncology. RadioGraphics. … Continue reading Additional information regarding PET radiotracers in prostate cancer is available at: https://clinical.aimspecialtyhealth.com/pet-radiotracers-in-prostate-cancer/.